CUV 1.61% $14.68 clinuvel pharmaceuticals limited

re: Ann: Clinuvel commences US Phase III tria... It's about as...

  1. 648 Posts.
    re: Ann: Clinuvel commences US Phase III tria... It's about as safe a bet for approval in Europe as you're going to get except for a drug that is attempting to get generic approval.

    The downside is:
    1 - we don't know when European regulators will make a decision
    2 - the market still doesn't appear to be too jazzed about EPP
    3 - if the overall markets get slammed by the stuff going on in Europe (Greece, etc.), then Australian markets will suffer as well
    4 - the company's cash position, which I still suspect is keeping a lot of people on the sidelines

    JMO
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.